Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-999 in Advanced Solid Tumors
NCT04084366Phase 2Terminated
- Sponsor
- OBI Pharma
- Start
- Nov 2019
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OBI-999 in solid tumor (advanced stage), sponsored by OBI Pharma. Started Nov 2019; status: terminated.
02
Drugs
OBI-999
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04084366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084366.